Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platanus racemosa pollen is a non-standardized allergenic extract derived from the pollen of the California sycamore tree. [5-1, 9, 12] It is used for both the diagnosis and treatment (immunotherapy) of individuals with immediate hypersensitivity allergies to this specific pollen. [5-4] For diagnostic purposes, it is applied via skin testing (percutaneous or intradermal routes) to elicit a localized allergic reaction, characterized by histamine release, in sensitized patients. [5-1, 5-5] As a therapeutic agent, it is administered subcutaneously to desensitize the immune system over time, a process which is believed to involve the induction of cell-mediated immunity and an increase in the production of specific IgG antibodies that can block the allergic response. [5-1, 5-5] The product is manufactured and distributed by Greer Laboratories, Inc. (now Stallergenes Greer) and is approved under a Biologic License Application (BLA). [4-2, 4-3, 5-5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platanus racemosa pollen.